Related Experiment Video

Updated: Aug 10, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.9K

MiniMed 780G Six-Month Use in Children and Adolescents with Type 1 Diabetes: Clinical Targets and Predictors of

Fortunato Lombardo1, Stefano Passanisi1, Angela Alibrandi2

  • 1Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi," University of Messina, Messina, Italy.

Diabetes Technology & Therapeutics
|February 10, 2023
PubMed

Insights

The MiniMed™ 780G system effectively improved glycemic control in children and adolescents with type 1 diabetes. Factors like younger age and shorter disease duration predicted better outcomes with this advanced hybrid closed-loop system.

Area of Science:

  • Pediatric Endocrinology
  • Biomedical Engineering
  • Diabetes Technology

Background:

  • Type 1 diabetes management in pediatric populations presents unique challenges.
  • Advanced hybrid closed-loop systems offer potential for improved glycemic control.
  • Real-world data on the MiniMed™ 780G system in children is crucial.

Purpose of the Study:

  • To evaluate glycemic outcomes in children and adolescents using the MiniMed™ 780G system for the first 6 months.
  • To identify demographic and clinical factors associated with achieving therapeutic goals.

Main Methods:

  • Multicenter observational real-world study.
  • Collected demographic, anamnestic, and clinical data.
  • Analyzed ambulatory glucose profile data at 3 and 6 months post-activation.

Main Results:

  • The MiniMed™ 780G system demonstrated effectiveness in achieving key glycemic targets (TIR, CV, GMI, TBR) in pediatric patients.
  • 44% of participants concomitantly met all primary clinical targets.
  • Older age, shorter disease duration, and shorter active insulin time were predictors of optimal glucose control.

Conclusions:

  • The MiniMed™ 780G system is effective and safe for pediatric type 1 diabetes management.
  • Personalized training is recommended for younger patients and those with long disease duration for optimal use.

Keywords:
Advanced hybrid closed loopCoefficient of variationEducationGlycated hemoglobinPediatricsTechnologyTime in range

More Related Videos

Simple Continuous Glucose Monitoring in Freely Moving Mice03:25

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

5.7K
Author Spotlight: Exploring the Long-Term Health Impacts of Intracytoplasmic Sperm Injection on Offspring06:11

Author Spotlight: Exploring the Long-Term Health Impacts of Intracytoplasmic Sperm Injection on Offspring

Published on: May 17, 2024

727

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
223
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
325
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.8K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
309
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
203